
- /
- Supported exchanges
- / US
- / VKTX.NASDAQ
Viking Therapeutics Inc (VKTX NASDAQ) stock market data APIs
Viking Therapeutics Inc Financial Data Overview
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Viking Therapeutics Inc data using free add-ons & libraries
Get Viking Therapeutics Inc Fundamental Data
Viking Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-22
- EPS/Forecast: -0.3113
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Viking Therapeutics Inc News

Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity
Key Points Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all downside hedges. Despite trading near 52-week lows due to biote...


Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity
Key Points Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all downside hedges. Despite trading near 52-week lows due to biotec...

Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns.
Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with Lilly and Novo. Continue Reading View Comments

Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts
In the latest close session, Viking Therapeutics, Inc. (VKTX) was up +1.7% at $28.19. The stock outperformed the S&P 500, which registered a daily gain of 0.83%. Elsewhere, the Dow saw an upswing of 0...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.